

1st Translational Research Conference
Chronic Lymphocytic Leukaemia
Paris, France
March 20-22, 2020

Chairs: Jennifer Brown (Boston), Paolo Ghia (Milan), Michael Hallek (Cologne)

Friday, March 20, 2020

08:15–08:30 Welcome

SESSION I – The genomic and epigenomic landscape of CLL and clinical consequences

Chair (s): TBA

08:30-08:45 Genetic predisposition

Jennifer Brown (Boston)

08:45-08:50 *Discussion*

08:50-09:05 Genetic landscape

Cathy Wu (Boston)

09:05-09:10 *Discussion*

09:10-09:25 Ibrutinib

Jennifer Woyach (Columbus)

09:25-09:30 *Discussion*

09:30-09:45 Epigenetic landscape

Chris Oakes (Columbus)

09:45-09:50 *Discussion*

09:50-10:05 Risk stratification: future perspective
(complex karyotype? NOTCH1?)

Panagiotis Baliakas (Uppsala)

10:05-10:10 *Discussion*

10:10-10:40 *Panel discussion*

10:40-11:10 *Coffee Break*

SESSION II – The role of BCR activation and signalling for CLL

Chair (s): TBA

11:10-11:25 BCR isotypes/autonomous signalling

Hassan Jumaa (Ulm)

11:25-11:30 *Discussion*

11:30-11:45 The latest news on stereotypes

Kostas Stamatopoulos (Thessaloniki)

11:45-11:50 *Discussion*

11:50-12:05 Novel BCR targets

Andrew Steele (Southampton)

12:05-12:10 *Discussion*

12:10-12:25 Next generation BTK inhibitors (covalent/non-covalent?) Constantine Tam (Melbourne)
12:25-12:30 *Discussion*

12:30-12:37 Short talk TBA
12:37-12:40 *Discussion*

12:40-13:10 *Panel discussion*

13:10-14:50 *Lunch*

13:30-14:30 Possible slot for a satellite symposium

SESSION III – Therapeutic options for CLL

Chair(s): TBA

15:00-15:15 Ibrutinib for everybody Jennifer Woyach (Columbus)
15:15-15:20 *Discussion*

15:20-15:35 Ibrutinib for a small subgroups only Florence Cymbalista (Paris)
15:35-15:40 *Discussion*

15:40-15:55 MURANO and MRD John Seymour (Melbourne)
15:55-16:00 *Discussion*

16:00-16:15 CLL14 update Kirsten Fischer (Cologne)
16:15-16:20 *Discussion*

16:20-16:27 Short talk TBA
16:27-16:30 *Discussion*

16:30-17:00 *Panel discussion*

17:00-17:30 *Coffee break*

SESSION IV – Long term follow up of clinical trials versus real world data (Outside Clinical Trials data-OCT)

Chair (s): TBA

17:30-17:45 Ibrutinib trials Alessandra Tedeschi (Milan)
17:45-17:50 *Discussion*

17:50-18:05 Ibrutinib real world George Follows (Cambridge)
18:05-18:10 *Discussion*

18:10-18:25 Venetoclax trials Matthew Davids (Boston)
18:25-18:30 *Discussion*

18:30-18:45 Venetoclax / PI3K real world Anthony Mato (New York)
18:45-18:50 *Discussion*

18:50-18:57 Short talk TBA
18:57-19:00 *Discussion*

19:00-19:30 *Panel discussion*

19:30 ***Get together and poster walks (stand up cocktails and buffet dinner for all)***

09:00-10:00 Possible slot for a satellite symposium

09:00-10:00 3 Simultaneous Meet the Expert sessions (non-clinical)

- | | |
|--|-----------------------------|
| 1. Prognostic and predictive markers | Barbara Eichhorst (Cologne) |
| 2. Resistance to ibrutinib: what to do | Jennifer Brown (Boston) |
| 3. First line therapy: continuous or time limited treatment? | Michael Hallek (Cologne) |

10:00-10:30 *Coffee break*

SESSION V – The increasing role of the leukaemic microenvironment

Chair (s): TBA

- | | |
|---|----------------------------|
| 10:30-10:45 Role of stromal cells | Andrea Brendolan (Milan) |
| 10:45-10:50 <i>Discussion</i> | |
| 10:50-11:05 Tissue recirculation of leukaemic cells | Silvia Deaglio (Turin) |
| 11:05-11:20 <i>Discussion</i> | |
| 11:20-11:35 Role of T cells | Arnon Kater (Amsterdam) |
| 11:35-11:40 <i>Discussion</i> | |
| 11:40-11:55 Immunomodulatory effects of kinase inhibitors | Adrian Wiestner (Bethesda) |
| 11:55-12:00 <i>Discussion</i> | |
| 12:00-12:07 Short talk | TBA |
| 12:07-12:10 <i>Discussion</i> | |
| 12:10-12:40 <i>Panel discussion</i> | |
| 12:40-14:30 <i>Lunch</i> | |

13:20-14:20 Possible slot for a satellite symposium

SESSION VI – Therapeutic options 2: The use of cellular and non-cellular immunotherapies in CLL

Chair (s): TBA

- | | |
|--|---------------------------|
| 14:30-14:45 Next generation PI3K inhibitors | Peter Hillmen (Leeds) |
| 14:45-14:50 <i>Discussion</i> | |
| 14:50-15:05 Novel inhibitors at preclinical level
(MCL1 & CDK inhibitors) | Alexey Danilov (Portland) |
| 15:05-15:10 <i>Discussion</i> | |
| 15:10-15:25 Optimizing the use of BH3 Mimetics in CLL | Eric Eldering (Amsterdam) |
| 15:25-15:30 <i>Discussion</i> | |
| 15:30-15:45 CAR-T cells | David Maloney (Seattle) |
| 15:45-15:50 <i>Discussion</i> | |
| 15:50-16:05 Allo-transplant | Peter Dreger (Heidelberg) |
| 16:05-16:10 <i>Discussion</i> | |

16:10-16:40 *Panel discussion*

16:40-17:10 *Coffee break*

SESSION VII – Efficacy through safety

Chair (s): TBA

17:10-17:25 *Cardiologist* Javid Moslehi (Nashville)

17:25-17:30 *Discussion*

17:30-17:45 *Dermatologist* Nicole LeBoeuf (Boston)

17:45-17:50 *Discussion*

17:50-18:05 *Infectious diseases* Pierluigi Viale (Bologna)

18:05-18:10 *Discussion*

18:10-18:25 *Gastroenterology* Stefano Fagioli (Bergamo)

18:25-18:30 *Discussion*

18:30-19:00 *Panel discussion*

Free evening

Sunday, March 22, 2020

07:30-08:30 3 Simultaneous Breakfast Meet the Expert Sessions (clinical)

1. Treatment of relapsed CLL

Paolo Ghia (Milan)

2. Management of novel drugs side effect

Carol Moreno (Barcelona)

3. MRD assessment

Andy Rawstron (Leeds)*

SESSION VIII – Clonal heterogeneity, clonal evolution and mechanisms of drug resistance

Chair (s): TBA

08:40-08:55 *Clonal evolution* Davide Rossi (Bellinzona)

08:55-09:00 *Discussion*

09:00-09:15 *PI3K*

Jennifer Brown (Boston)

09:15-09:20 *Discussion*

09:20-09:35 *Venetoclax*

John Seymour (Melbourne)

09:35-09:40 *Discussion*

09:40-09:47 *Short talk*

TBA

09:47-09:50 *Discussion*

09:50-10:20 *Panel discussion*

10:20-10:50 *Coffee break*

SESSION IX – Contrasting therapeutic concepts:

Chair (s): TBA

10:50-11:05	MRD as a dynamic endpoint	Peter Hillmen (Leeds)
11:05-11:10	<i>Discussion</i>	
11:10-11:25	Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction in lymphoid malignancies including CLL	David M. Kurtz (Stanford)
11:25-11:30	<i>Discussion</i>	
11:30-11:45	Sequential vs combination treatments	Bill Wierda (Houston)
11:45-11:50	<i>Discussion</i>	
11:50-12:05	Time limited vs continuous treatments	Barbara Eichhorst (Cologne)
12:05-12:10	<i>Discussion</i>	
12:10-12:40	<i>Panel discussion</i>	
12:40-12:50	<i>Closing Remarks</i>	

MEETING CLOSURE

**pending confirmation*